Article thumbnail

Modulation of Cytokine and Cytokine Receptor/Antagonist by Treatment with Doxycycline and Tetracycline in Patients with Dengue Fever

By J. E. Z. Castro, I. Vado-Solis, C. Perez-Osorio and T. M. Fredeking


Dengue virus infection can lead to dengue fever (DF) or dengue hemorrhagic fever (DHF). Disease severity has been linked to an increase in various cytokine levels. In this study, we evaluated the effectiveness of doxycycline and tetracycline to modulate serum levels of IL-6, IL-1B, and TNF and cytokine receptor/receptor antagonist TNF-R1 and IL-1RA in patients with DF or DHF. Hospitalized patients were randomized to receive standard supportive care or supportive care combined with doxycycline or tetracycline therapy. Serum cytokine and cytokine receptor/antagonist levels were determined at the onset of therapy and after 3 and 7 days. Cytokine and cytokine receptor/antagonist levels were substantially elevated at day 0. IL-6, IL-1β, and TNF remained at or above day 0 levels throughout the study period in untreated patients. Treatment with tetracycline or doxycycline resulted in a significant decline in cytokine levels. Similarly, IL-1RA and TNF-R1 serum concentrations were elevated at baseline and showed a moderate increase among untreated patients. Both drugs resulted in a significant rise in IL-1Ra levels by day 3 in patients. In contrast, treatment did not affect a similar result for TNF-R1. When compared to the control group, however, a significant rise post-treatment was seen upon intragroup analysis. Further analysis demonstrated that doxycycline was significantly more effective at modulating cytokine and cytokine receptor/antagonist levels than tetracycline

Topics: Clinical Study
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). A .M .M a r t y ,P .B .J a h r l i n g ,a n dT .W .G e i s b e r t ,“ V i r a l hemorrhagic fevers,”
  2. (2003). Anti-cytokine therapeutics and infections,” Vaccine,
  3. (2009). Anticytokine therapeutics: history and update,”
  4. (2008). B o z z a ,O .G .C r u z ,S .M .O .Z a g n ee ta l . ,“ M u l t i p l e x cytokine profile from dengue patients: MIP-1beta and IFNgamma as predictive factors for severity,”
  5. (2003). Changes in immune parameters and their correction in human cases of tick-borne encephalitis,”
  6. (2007). Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors,”
  7. (2008). Cutting edge: mechanismofenhancementofinvivocytokineeffectsbyanticytokine monoclonal antibodies,”
  8. (2008). Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza
  9. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges,”
  10. (1999). Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity,”
  11. (2004). Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated
  12. (2002). Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem
  13. (1998). Fr¨ olich, “Anti-inflammatory cytokine profile and mortality in febrile patients,”
  14. (1995). High levels of interleukin 10 in serum are associated with fatality in meningococcal disease,”
  15. (2006). Human malarial disease: a consequence of inflammatory cytokine release,”
  16. (2006). Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines,”
  17. (1992). Imbalance between tumour necrosis factoralpha and soluble TNF receptor concentrations in severe meningococcaemia,”
  18. (2008). Immunomodulatory properties of antibiotics,” Current Molecular Pharmacology,v o l .1 ,n o .1 ,p p .
  19. (1996). Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome,”
  20. (2008). Many cytokines are very useful therapeutic targets in disease,”
  21. (2007). Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome
  22. (1998). Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever,”
  23. (2004). R.M.Bonelli,A.K.H odl,P .H ofmann,andH.P .K apfhammer , “Neuroprotection in Huntington’s disease: a 2-year study on minocycline,”
  24. (1993). Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in dengue-infected patients,”
  25. (2003). Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity,”
  26. (1994). The biological properties of interleukin-1,”
  27. (2007). The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study,” Multiple Sclerosis,
  28. (2002). The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome,” Thrombosis and Haemostasis,